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ABSTRACT 1 
Nuclear transfection of DNA into mammalian cells is challenging yet critical for many biological 2 
and medical studies. Here, by combining cell squeezing and electric-field-driven transport in a 3 
device that integrates microfluidic channels with constrictions and microelectrodes, we 4 
demonstrate nuclear delivery of plasmid DNA within 1 hour after treatment, the most rapid DNA 5 
expression in a high-throughput setting (up to millions of cells per minute per device). Passing 6 
cells at high speed through microfluidic constrictions smaller than the cell diameter mechanically 7 
disrupts the cell membrane, allowing a subsequent electric field to further disrupt the nuclear 8 
envelope and drive DNA molecules into the cytoplasm and nucleus. By tracking the localization 9 
of the ESCRT-III (endosomal sorting complexes required for transport) protein CHMP4B, we 10 
show that the integrity of the nuclear envelope is recovered within 15 minutes of treatment. We 11 
also provide insight into subcellular delivery by comparing the performance of the disruption-12 
and-field-enhanced method with those of conventional chemical, electroporation, and manual-13 
injection systems. 14 
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 1 
Intracellular delivery, the introduction of exogenous materials into cells, is essential to many 2 
studies in basic biology and biomedical research (1, 2). A multitude of techniques exists for cell 3 
transfection, including biological, chemical, and physical methods (3). Biological/chemical 4 
methods usually rely on carriers such as viruses, vesicles, peptides or nanoparticles (4-7). 5 
Physical methods primarily use membrane-disruption techniques such as microinjection, 6 
electroporation, laser optoporation, and particle bombardment for gene delivery (8-13). Although 7 
electroporation has been widely used for DNA transfection since the early 1980s, the underlying 8 
mechanism of delivery is not completely understood in nucleated mammalian cells (14-19). In 9 
the electroporation process, DNA molecules accumulate and interact with the 10 
electropermeabilized plasma membrane during the electric pulse to form aggregates. Afterwards, 11 
those DNA aggregates are internalized into the cytoplasm and subsequently expressed (20-26). It 12 
is unlikely that DNA plasmids navigate through the viscous and crowded cytoplasm to reach the 13 
nucleus simply by diffusion (27, 28). Microtubule and actin networks have been proposed to play 14 
an important role in DNA transportation within the cytoplasm, and the time-scale of such 15 
processes can be hours long depending on the cell type (22). The lack of detailed mechanistic 16 
understanding and the complex nature of DNA transfer between the plasma membrane and 17 
nucleus limit our ability to enhance electroporation performance. Moreover, the strong fields 18 
used in current electroporation techniques can lead to significant damage or death (25, 26). Nano 19 
structure based methods have demonstrated potential for effective gene transfection by 20 
penetrating DNA-loaded nanoneedles into the cell, or by diffusion/electrophoresis through a 21 
nanostraw (29-31). However, such methods typically have relatively low throughput. Moreover, 22 
the nuclear envelope rupture is not well investigated. Hence, substantial interest remains in 23 
creating techniques that can quickly and directly deliver DNA to the nucleus in a large number of 24 
cells with controllable nuclear envelope damage.  25 
One example of a feasible strategy would involve the transient disruption of the cell plasma 26 
membrane and nuclear envelope followed by entry of the target material before resealing. Cell 27 
squeezing is a representative technique that enables delivery of a diversity of materials to 28 
numerous cell types by mechanically disrupting the plasma membrane and allowing diffusion to 29 
transport materials of interest into the cell cytosol (32-35). DNA delivery is, however, more 30 
complicated because DNA must enter the nucleus to perform its function and the cytosolic 31 
 4 
delivery results in the degradation of DNA before it can reach the nucleus, as reported for 1 
microinjection (11). Thus, passive diffusion of DNA is likely insufficient and active transport of 2 
the DNA to the nucleus is necessary to initiate gene expression. To address this challenge, we 3 
combine disruption of both plasma membrane and nuclear envelope with electric fields to 4 
enhance delivery – Disruption and Field Enhanced (DFE) delivery. Recent studies show that 5 
moderate nuclear envelope rupture could be rapidly repaired in an ESCRT (endosomal sorting 6 
complexes required for transport)-dependent manner, indicating a potential of reversible nuclear 7 
envelope rupture (36-39). Here, we use a microfluidic device to create rapid mechanical 8 
deformation by cell squeezing to disrupt the plasma membrane, followed by exposing the cell to 9 
an electric field that generates reversible nuclear envelope rupture and drives the negatively 10 
charged DNA into the nucleus and cytoplasm. With this device, we show a significant increase 11 
in efficiency and speed of DNA expression, as well as rapid nuclear localization akin to 12 
microinjection. Moreover, DNA plasmids are successfully delivered to both nucleus and 13 
cytoplasm at throughputs up to millions of cells per minute per device in continuous flow. We 14 
further investigate the disruption and repair of both plasma membrane and nuclear envelope, and 15 
their relation to intracellular and nuclear delivery. The DFE system also proves useful in co-16 
delivery of DNA, RNA, and proteins. 17 
DFE Design and Characterization 18 
In order to explore whether addition of an electric field would be able to promote delivery of 19 
DNA after squeezing, we constructed a microfluidic device with an electric pulse zone 20 
downstream of the constriction zone (Figure 1). Each device consisted of a set of parallel, 21 
identical constriction channels and a set of electrodes. Consistent with the existing squeeze 22 
design (32), 75 parallel channels with constriction zones were etched into a silicon wafer using 23 
deep reactive ion etching (DRIE). Subsequently, electrodes were incorporated into the DFE 24 
device section by anodic bonding of Pyrex patterned with electrodes (see figure S1 for more 25 
details of fabrication). Based on our previous observation for the best efficiency in intracellular 26 
delivery (32, 33) with cell squeezing, the width and length of the constriction were in the ranges 27 
4 - 10 µm and 10 - 30 µm, respectively. The length, width, and gap space between each electrode 28 
were 8 mm, 60 µm, and 40 µm, respectively, allowing the generation of sufficiently high electric 29 
field (~2 kv/cm) with low applied voltage. The duration and duty cycle of the electrical pulse 30 
 5 
applied to the device ranged from 50 - 500 s and 1% - 10%, commensurate with values 1 
commonly used for electroporation (26).  2 
We typically operated the DFE device at a throughput of 100 000 – 500 000 cells/s per chip per 3 
run (each run took 5-20 seconds). Each data point was the mean value of three collections. Each 4 
device could be reused 5-10 times before cell debris clogged the channels. At that point, devices 5 
were cleaned for reuse by flushing the device with 10% bleach buffer. A 50 – 100 µL mixture of 6 
cells and materials to be delivered was placed into the inlet reservoir and driven through the 7 
device with nitrogen pressure controlled by a regulator (32). The exposure time of the cells in the 8 
electrical field typically ranged from 10 – 100 ms, depending on the flow rate.  9 
Many parameters governed the performance of mechanical disruption and electrical delivery, 10 
including cell speed, constriction dimension, electrical pulse profile, strength, and number of 11 
pulses. We first performed a number of experiments to characterize DNA transfection with the 12 
DFE technique by treating a mixture of Hela cells and GFP plasmid DNA at different pulse 13 
amplitudes. After treatment, cells were incubated at 37 °C for 24 hours. GFP fluorescence 14 
measurements by flow cytometry characterized DNA expression. These experiments used a 15 
device with a constriction length of 10 µm and a constriction width of 6 µm, denoted as a 10-6 16 
DFE device. Our experimental results show that cell transfection reached above 60% and 90% 17 
when the applied amplitude increased to 8V and 10V respectively (Figure 2a red columns). As a 18 
control group, we treated cells using a device with the same electrical field and cell speed but no 19 
constriction structure (squeezing), corresponding to electroporation in microfluidic devices (flow 20 
EP). With cells experiencing only an electric field, the DNA transfection efficacy reached 60% 21 
after the applied amplitude increased to 14V (Figure 2a green columns). Both cases had similar 22 
cell viability (Figure 2b), suggesting that mechanical disruption dramatically enhanced the DNA 23 
delivery at lower field intensities while causing negligible additional damage to the cells.  24 
We also investigated the influence of cell speed on the transfection. Under an applied pulse of 25 
10V, the DNA expression decreased with increasing cell speed due to the reduced number of 26 
pulses the cell received as it traveled through the electric field (Figure S2). At cell speeds ~300 27 
mm/s, cell viability and DNA expression seem to best balance severe electric damage at low 28 
speed and mechanical damage at high speed. The delivery efficiency of membrane-impermeable 29 
Cascade Blue labeled 3-kDa dextran molecules to live Hela cells first dropped and then grew 30 
with increasing cell speed, indicating the dominant mechanism of delivery for this molecule 31 
 6 
switches from electrical field at low speed to mechanical disruption at high speed. The difference 1 
in delivery behavior between the 3kDa dextran and DNA molecules further highlight the 2 
significance of electrical field effect for DNA transfection.  3 
 DFE versus Microinjection, Flow EP, EP, and Cell Squeezing 4 
In order to gain further insight into the mechanism of DFE delivery, we carried out a 5 
comparative study with four widely used DNA transfection techniques: microinjection 6 
(Eppendorf microinjector 5242), Lipofection (lipofectormine 2000 from ThermoFisher), flow EP 7 
(microfluidics-based flow electroporation) and EP (conventional electroporation, using the 8 
NEON electroporation system from ThermoFisher, a common commercial electroporation tool). 9 
DNA expression was analyzed using flow cytometry after treatment with each technique. EP and 10 
flow EP showed similar expression kinetics as GFP gradually expressed throughout 24 hours 11 
after treatment (Figure 2 c and d). 70% of GFP expressing cells (cells that express GFP 12 
fluorescence after 48 hours) expressed GFP between 4-48 hours. In contrast, with microinjection 13 
and DFE, more than 80% of GFP expressing cells had measureable expression within the first 14 
hour post treatment, indicating that DNA transcription/translation occurred soon after treatment. 15 
The remaining 20% of ultimately GFP expressing cells had detectable expression 1 to 4 hours 16 
post treatment. Microinjection is broadly accepted as a means of facilitating direct injection of 17 
materials into the nucleus. The similar DNA expression kinetics for microinjection and DFE 18 
suggest that DNA delivered by DFE becomes accessible for transcription in the nucleus.  19 
For the Lipofection case, we found minimal GFP fluorescence in the first 4 hours post treatment, 20 
and more than 95% of transfected cells expressed GFP between 4 – 48 h after treatment. 21 
Fluorescence images of GFP expressed cells by DFE, EP, and Lipofection are shown in Figure 22 
S3. We further compared the fluorescence intensity of GFP in Hela cells as measured by flow 23 
cytometry (Figure S4). The DFE data display a peak in the fluorescence intensity that keeps 24 
increasing in intensity within the first 4 hours after treatment indicating that the DNA 25 
transcription/translation in most of cells occurred from a similar starting time point soon after 26 
treatment. In contrast, for EP and Lipofection, the fluorescence intensity has a flat distribution in 27 
the first 12 hours, suggesting that the time required for the DNA migration to nucleus and release 28 
from carrier varies from 4 to 24 hours or even longer. DFE has lower RSD (relative standard 29 
deviation) and higher NMI (normalized mean intensity) than EP, indicating DFE has better 30 
 7 
transfection uniformity and level (more transfection) than EP. Lipofection has the highest NMI, 1 
which could be due to the fact the DNA molecules are confined in lipid nano particles while in 2 
DFE and EP DNA molecules are distributed throughout the solution.  3 
To further explore the working mechanism of DFE, we directly visualized the distribution of 4 
DNA at single cell level using CY3 labeled plasmid DNA (Figure 3). Cells were first incubated 5 
with DAPI (ThermoFisher) and Cell Mask green plasma membrane stain (ThermoFisher) for 6 
nuclear and membrane staining, and then mixed with labeled DNA right before treatment with 7 
DFE, EP, and Squeezing. After treatment, cells were incubated in culture medium for 3-5 8 
minutes and then fixed. Optical measurements were carried out using a Nikon A1R confocal 9 
microscope. When an electric pulse of 15ms/1200V, known to permeabilize cells, was applied in 10 
NEON electroporation system, a sharp CY3 fluorescence spots appeared at the plasma 11 
membrane level, indicating the absorption and accumulation of DNA on the membrane (Figure 12 
3b, see Figure S5 for additional results). This result is consistent with previous studies that 13 
demonstrate embedding of DNA into the plasma membrane. In Squeezing, no fluorescence of 14 
labeled DNA was detected in the cytoplasm with the confocal microscope. In DFE, we found 15 
labeled DNA fluorescence distributed in the cytoplasm, nucleus, and plasma membrane (Figure 16 
3c, see Figure S6 for additional results). The bright spots on the plasma membrane are DNA 17 
complexes formed as in conventional electroporation. Importantly, the direct visualization of 18 
DNA in the cytoplasm and nucleus further supports the hypothesis that DFE is capable of more 19 
effective delivery of DNA and indicates that the mechanism of action of the DFE system is likely 20 
distinct from electroporation or squeezing alone. These observations are further characterized by 21 
the relative fluorescence intensity profiles (Figure 3d) showing the DNA distribution along the 22 
dashed line across the single cells in Figures 3 a-c treated by squeezing, EP, and DFE. The 23 
higher fluorescence intensity in the nucleus than in cytoplasm after DFE could be attributed to 24 
(1) degradation of DNA in the cytoplasm by the surrounding DNase and subsequent outward 25 
diffusion of Cy3 dye detached from the degraded DNA; or (2) more DNA trapping in the dense 26 
nucleus than surrounding cytosol as DNA transits through the cell in the electric field. Combined 27 
with our observations of rapid DNA expression, either case demonstrates that disruption and 28 
field enhanced delivery facilitates efficient delivery of DNA directly to the nucleus.  29 
The ESCRT III complex is involved in repair of both plasma membrane and nuclear envelope 30 
rupture (36-39). We used HeLa cells expressing GFP-tagged CHMP4B, an important ESCRT III 31 
 8 
complex subunit, to study the nuclear envelope rupture and repair in DFE. We can induce 1 
recruitment of CHMP4B-GFP at the wounding site near the nuclear envelope using 2 
microinjection (Figure S7). In DFE, CHMP4B-GFP formed transient foci at the site of both 3 
nuclear envelope and plasma membrane (Figure 4a). In EP and Squeezing, CHMP4B-GFP was 4 
only recruited to plasma membrane. CHMP4B-GFP localized to the site of both plasma and 5 
nuclear membrane at 1-2 minutes right after membrane disruption to repair damage, and 6 
decreased after resealing (Figure 4 b and c, figure S8). This suggests that DFE could generate 7 
reversible disruption on both plasma membrane and nuclear envelope, a critical step for nuclear 8 
delivery.  9 
Discussion  10 
Intracellular delivery of nucleic acids is a challenging first step for an abundance of biological 11 
studies and applications. However, the current leading methods for DNA transfection, such as 12 
electroporation and lipofection, rely on a delayed trafficking of DNA to the nucleus. On the other 13 
hand, mechanical and other permeabilization techniques that deliver DNA directly to the 14 
cytoplasm often fail to achieve nuclear penetration and subsequent expression. Here, the 15 
proposed DFE concept combines the efficacy of mechanical membrane disruption with the 16 
driving force of a field – thus potentially maintaining the robust and rapid delivery capabilities of 17 
mechanical disruption while enhancing nuclear delivery of plasmids. DFE performance is likely 18 
a nonlinear combination of mechanical disruption and electrical delivery, each of which are 19 
influenced by complex sets of parameters. The choice of the buffer solution medium is a 20 
challenge. Commercial available buffers (including electroporation buffer from NEON and 21 
Eppendorf) works well for electric delivery, but not for cell squeezing based membrane 22 
disruption. Phosphate buffered saline (PBS) works well for cell squeezing, but not for electric 23 
delivery owing to its high conductivity, which produces electrolytic effects including changes in 24 
temperature, pH, and the chemical composition of the solution in proportion to the applied 25 
voltage. The hypo-osmolar buffer we used here is compatible with both mechanical disruption 26 
and electric delivery process. As expected, we found that hypo-osmolar buffer enlarged cell size, 27 
made the plasma membrane more susceptible to disruption (40), and subsequently lowered the 28 
cell velocity required for mechanical disruption. The use of hypo-osmolar buffer also facilitated 29 
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effective electric delivery (41). Lower electric field strength for electric delivery could be used at 1 
low cell speeds to protect electrodes and avoid electrolysis.  2 
DNA transport from plasma membrane to nucleus and subsequent transcription is a complex, 3 
most likely active, process that can take hours and may vary dramatically among different cell 4 
types. This process is essential in electroporation and carrier-based methods such as Lipofection. 5 
We have demonstrated that DFE is able to deliver DNA directly into the nucleus by providing a 6 
driving force to move DNA across a mechanically disrupted plasma membrane. The mechanical 7 
disruption decreases the plasma membrane barrier function to achieve an enhanced electrical 8 
delivery. The post-squeezing electric field might also alter distribution of openings in the 9 
membrane (42), to facilitate intracellular delivery. To our knowledge, the DFE experiments 10 
represent the most rapid expression of plasmid DNA in a high throughput setting (up to a few 11 
million cells per device per minute). The throughput could be further improved by adding more 12 
parallel microchannels on the chip or operating multiple devices in parallel. As shown in Fig. S2, 13 
the increase of diffusion-based delivery coincided with decreasing DNA transfection when 14 
increasing cell speed, this is due to the inverse dependence between cell squeezing speed and 15 
electric field exposure. High cell speed enhances strong mechanical disruption and thus more 16 
diffusive delivery, it also leads to a shorter exposure time in the electric field, causing lower 17 
electrical field driven delivery. Such interdependence is a limitation of the current version of the 18 
device. 19 
The DNA expression dynamics of Lipofection in Figures 2 c and d reveal that DNA transfer to 20 
the nucleus and subsequent transcription can require over 4 hours in Hela cells. DNA expression 21 
with conventional electroporation was slightly faster. There is ongoing debate regarding how 22 
DNA migrates into the nucleus during the electroporation process (15). Some hypothesize that 23 
electric pulse permeabilizes the cell membrane and electrophoresis drives DNA directly into the 24 
nucleus, while others observe that DNA first form aggregates at electropermeabilized areas of 25 
the plasma membrane during electric pulse and then migrates toward the nucleus through a 26 
biologically active process (17, 18, 25, 26). In our EP results, 20% of transfected cells expressed 27 
GFP within the first hour and 80% expressed throughout the next 20 hours. This could be an 28 
indication that both of the aforementioned mechanisms occurred in EP. The small portion of 29 
cells that express GFP immediately after treatment may involve direct electrophoresis of DNA 30 
into the nucleus while the majority of cells that expressed GFP after 4 hours must first transport 31 
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the DNA to the nucleus for expression, as in the case of Lipofection. Future studies could 1 
integrate a cell trap structure in the electric field downstream of the mechanical disruption to 2 
visualize DNA migration through the mechanically induced disruption in the plasma membrane.  3 
Recently ESCRT-III proteins have been shown to be involved in both plasma and nuclear 4 
membrane repair (36-39). We used HeLa cells expressing GFP-tagged CHMP4B, an important 5 
subunit of ESCRT-III complex, to monitor and measure the membrane dynamics in DFE. The 6 
recruitment of CHMP4B-GFP foci at both plasma and nuclear membrane after DFE treatment 7 
reveals that both membrane systems were disrupted and resealed, which is a critical step for 8 
nuclear delivery. In Squeezing and EP, however, CHMP4B-GFP only localized at the plasma 9 
membrane, indicating that nuclear envelope rupture did not occur at detectable levels. ESCRT 10 
proteins, including CHMP4B, are involved in the repair of small membrane wounds less than 11 
100 nm (36). This may explain why fewer CHMP4B-GFP foci were observed after squeezing 12 
compared to EP and DFE. It is known that electric fields usually generate pores in the range of a 13 
few nm or tens of nm, while mechanical disruption in Squeezing at high flow rates could 14 
generate larger wounds or prompt membrane plasma repair via pathways other than ESCRT-15 
mediated processes (32). The recruitment of CHMP4B-GFP to both plasma and nuclear 16 
membrane wounds occurred from1-2 minutes after the disruption, and nuclear membrane repair 17 
was completed by about 10-15 minutes post disruption, about 5 minutes slower than plasma 18 
membrane resealing. Such repair dynamics are consistent with recently published reports (36-19 
38). 20 
DFE delivery combines microfluidic-based membrane disruption and field effects to achieve 21 
potentially greater efficacy than either individual approach. The mechanical disruption 22 
techniques, such as squeezing, have shown significant success in delivery of a variety of 23 
materials, including proteins and nanomaterials, to a diversity of cell types with minimal toxicity, 24 
but have had limited success with DNA, presumably due to ineffective nuclear delivery. In DFE, 25 
we have demonstrated a successful co-delivery of DNA plasmid, mRNA, and protein (APC 26 
mouse IgG1 k Isotype Ctrl antibody, Figure S9). The results show that DNA and mRNA are 27 
significantly dependent on the electric field, while the protein delivery is more dependent on 28 
mechanical disruption. In mouse Embryonic Stem Cells (mESC), we achieved DNA transfection 29 
of 19% and 36% at 10V and 14V respectively in DFE (Figure S10 a-c). By combining 30 
mechanical disruption and electric field effects, our DFE concept has demonstrated reversible 31 
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nuclear and plasma membrane disruption for both nuclear and cytosolic delivery, and is capable 1 
of co-delivering proteins and nucleic acids, characteristics that are difficult to accomplish with 2 
any of the aforementioned methods individually.  3 
Outlook 4 
Our DFE system is able to deliver DNA molecules into the nucleus and cytoplasm at high 5 
throughput with minimal cell damage. We anticipate that such direct and rapid nuclear delivery 6 
will find utility in studies of fundamental biology and biomedical applications such as the 7 
implementation of more robust DNA transfection for cell-based therapies. Future work will 8 
focus on developing a deeper understanding of the interplay between the membrane disruptions, 9 
electric field enhanced transportation, and the cell response, thus facilitate effective 10 
implementation in more challenging cell types and applications. One would expect the parameter 11 
space of DFE systems to be more complex than squeezing or electroporation alone as its efficacy 12 
relies on the synergistic interplay of relevant parameters from both techniques. Nuclear envelope 13 
disruptions in DFE can be explored further. Nevertheless, the DFE concept shows potential to 14 
enable more rapid delivery and expression compared to existing transfection technologies, and 15 
paves the way toward more targeted delivery strategies at the subcellular level. 16 
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METHODS 1 
Device Fabrication and Experimental Setup. A silicon wafer was bonded to a Pyrex 2 
wafer to form the DFE microfluidic device. Two major steps were involved in the fabrication: 3 
(1) the fabrication of microfluidic channels on silicon wafer, and (2) the fabrication of 4 
microfluidic electrodes on Pyrex wafer (see Supporting Information for more details). The 5 
device was mounted onto a holder with inlet and outlet reservoirs (more details in ref. 29). 6 
Electric pulses were generated from a function generator (Agilent 33220A) and gained through 7 
an amplifier to drive the device through the wire bonded to the electrode pads using conductive 8 
epoxy. Cells were suspended to a density of 1-5 X 106 cells/mL in a modified buffer (25mM 9 
KCl, 0.85 mM K2HPO4, 0.3mM KH2PO4, 36mM myo-inositol, PH 7.2, conductivity 3.5mS/cm 10 
at 25 °C, ref. 37) for experiment. Solutions of cells, mixed with desired delivery material, were 11 
placed in the inlet reservoir. This reservoir was then connected to a compressed air line 12 
controlled by a regulator. A pressure (0-20psi) was used to drive the fluid through the device, 13 
and at the same time, electric pulses were applied to the device as cells flowed through. Cells 14 
were collected from outlet reservoir and subjected to further treatment. 15 
   16 
Cell culture. HeLa cell line (Hela-Kyoto) was provided by Hyman Lab, Max Planck Institute, 17 
Dresden, Germany. Authentication Test was performed by Multiplex. Cells were routinely 18 
cultured in 75 T flasks containing 20mL of DMEM culture medium supplemented with 10% 19 
fetal bovine serum (FBS, Invitrogen 16000), at 37 °C in a humidified atmosphere containing 5% 20 
CO2. hESCs (H13, WiCell, Wisconsin) were grown on an inactivated mouse embryonic 21 
fibroblast (MEF) feeder layer, provided by Jeff Karp Lab in Brigham and Women’s Hospital, 22 
Harvard Medical School. mESCs (129P2/OlaHsd, provided by Richard Sherwood lab from 23 
Brigham and Women's Hospital, Harvard Medical School) were maintained on gelatin-coated 24 
plates in mESC medium composed of Knockout DMEM (Life Technologies) supplemented with 25 
15% defined FBS (HyClone), 0.1 mM nonessential amino acids (Life Technologies), 1% 26 
Glutamax (Life Technologies), 0.55 mM 2-mercaptoethanol (Sigma), 1× ESGRO LIF 27 
(Millipore), 5 nM GSK-3 inhibitor XV and 500 nM UO126. Cells were regularly tested for 28 
mycoplasma. HeLa cells expressing CHMP4B-GFP were a generous gift of the Tony Hyman lab 29 
 13 
(43). They were maintained in geneticin-containing media and FACS sorted prior to 1 
experiments. 2 
 3 
Delivery Materials. Fluorescently labeled molecules, including dextran and plasmid DNA, 4 
were mixed with cell solution at a concentration of 0.1 mg/mL. GFP DNA plasmid was used to 5 
measure the DNA transfection.  6 
 7 
Flow Cytometry. For quantitative analysis of cells after DNA delivery, cells were treated with 8 
trypsin 24 hours after delivery experiment and washed twice with PBS (200 uL per well in V-9 
bottom 96-well plate). They were then resuspended in PBS solution supplemented with 3% FBS, 10 
1% F-68 Pluronics, and 1 ug/mL propidium iodide (Sigma) for the analysis using LSR Fortessa 11 
(BD Biosceinces).  12 
 13 
Lipofection. Lipofectamine 2000 DNA transfection kit was used to represent Lipofection 14 
technique. The DNA-lipid complex was prepared by combining 2 uL of Lipofection 2000 15 
reagent in 100 uL of Opti-MEM medium with 2 ug of DNA plasmid in 100 uL of Opti-MEM 16 
medium, followed by 5 minutes of incubation in room temperature. The DNA-lipid complex 17 
solution was added to cell sample at the ratio of 1:30. More details can be found in the product 18 
protocol (Lipofection 2000, Life Technologies).  19 
 20 
Microinjection. The microinjection of DNA plasmid into Hela cells was operated by 21 
experienced staff. 30 cells were injected for each condition. The DNA concentration in the buffer 22 
for injection is 0.1 ug/mL. A pressure of 60hPa and a duration of 0.2 s were used for each 23 
injection.  24 
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 1 
Fig. 1. Device structure and working mechanism. (a) Schematic drawing illustrating the working principle: 2 
(i) mechanical disruption of the cell membrane as the cell passes through the constriction, and (ii) he 3 
subsequent electric pulses driving DNA into the cytoplasm and nucleus through the disrupted membrane. 4 
(b) Magnification of a set of identical parallel microfluidic constriction etched into a silicon wafer (left), and 5 
a set of electrodes deposited on a Pyrex wafer (right). (c) An optical image of a finished device realized 6 
by bonding silicon and Pyrex wafers. The scale bar is 1 mm. Details of device fabrication are in Figure S1. 7 
 8 
 9 
Fig. 2. DNA transfection performance and expression dynamics depend on the applied electric field and 10 
methods. DNA transfection efficiency (a) and cell viability (b) at 24 h after treatment as a function of 11 
applied electric amplitude (voltage). The introduction of mechanical disruption prior electrical delivery 12 
significantly enhances the DNA transfection, while bringing negligible damage to cell viability. GFP 13 
plasmid DNA transfection efficiency and cell viability were measured by flow cytometry 24 hours after 14 
delivery treatment using propidium iodide staining. (c) GFP expression efficiency as a function of time 15 
post treatment. Efficiency is defined as the GFP expressing cells over total live cells after treatment. A 10-16 
7 chip is used for mechanical disruption (S: cell squeeze) and DFE. A pulse of 0.1ms/10V at a frequency 17 
of 200Hz is used for flow EP (Microfluidic based flow electroporation), and a single pulse of 15ms/15000V 18 
is used in EP. (d) The dynamics of DNA expression is analyzed by measuring differential GFP expressing 19 
at different time points after treatment. More than 80% of transfected cells expressed GFP within 1 h after 20 
treatment in microinjection and DFE. In contrast, most of transfected cells in flow EP (60%), EP (70%) 21 
and LP2000 (95%) express GFP 4 – 48 h after treatment. The number of Hela cells in every treatment for 22 
each method is shown as well, indicating the throughput of each technique. Each data point is the mean 23 
value of triplicate and error bars represent ± s.d. 24 
 25 
 26 
Fig. 3. Visualization of the delivery of fluorescence labeled plasmid DNA (LDNA) to Hela cells. After 27 
nucleus and plasma membrane staining, Cells were mixed with Cy3 labeled plasmid DNA before 28 
transfection. After treatment, cells were washed with OPTI MEM, fixed with cell fixation kit, and ready for 29 
confocal imaging. (a) by only cell squeezing (S), no LDNA signal was detected in the cell, A 10-7 chip 30 
was used at cell speed of 500mm/s. (b) in electroporation (EP), an electric pulse of 15ms/1200V was 31 
applied using NEON electroporation system. DNA accumulation was found on the plasma membrane. (c) 32 
in DFE, a significant Cy3 fluorescence was observed filling cytoplasm and nucleus.10-7 DFE chip was 33 
used at cell speed of 500mm/s with applied electric pulse of 0.1ms (200Hz) at 10 V. Labeled DNA was 34 
detected in plasma membrane, cytoplasm and nucleus. (d), Relative fluorescence intensity profile over 35 
the dashed line across single cells in a, b, and c, shows the labeled DNA molecule distribution after 36 




Fig. 4. ESCRT-III recruitment for plasma membrane and nuclear envelope repair. CHMP4B-GFP 41 
expressing Hela cells were stained with DAPI to visualize the nucleus before treatment. After treatments 42 
of squeezing (S), EP, or DFE, cells were incubated in culture media, and fixed with a cell fixation kit at 43 
0.5, 1.5, 2.5, 3.5, 5.5, 10, and 15 minutes after treatment, and processed for confocal imaging. (a) 44 
Confocal images of representative cells at 1.5 minutes after no treatment (NC, Negative Control), 45 
squeezing (S), electroporation (EP), and DFE. CHMP4B-GFP foci are visible at both plasma membrane 46 
and nuclear envelope in DFE, but only at the plasma membrane in S and EP. Number of CHMP4B-GFP 47 
foci at plasma membrane (b) and nuclear envelope (c) after treatment of S, EP and DFE (10 cells at each 48 
data point). Original confocal fluorescent images are shown. Each data point represents the mean value 49 
of 10 cells and error bars represent ± s.d. 50 
 51 
